OBJECTIVE: To explore whether women who reported corticosteroid use during pregnancy were more likely to deliver an infant with hypospadias than women who did not. STUDY DESIGN: The analysis encompassed data on deliveries with an estimated due date between 1997 and 2004 from the National Birth Defects Prevention Study, a large population-based, case-control study conducted in the United States. Included were 1165 cases of moderate to severe hypospadias and 3000 nonmalformed male controls. RESULTS: The mothers of 39 cases (3.3%) and 62 controls (2.1%) reported using a corticosteroid medication during the period extending from 4 weeks before conception to 14 weeks after conception. The odds ratio (OR) for any corticosteroid exposure versus no corticosteroid exposure was 1.6 (95% confidence interval [CI] = 1.1 to 2.5); after adjustment for maternal race/ethnicity, education, age, and study site, it was 1.3 (95% CI = 0.8 to 2.0). Analyses by route of administration and specific component suggest that elevated ORs occurred only for nasal spray/inhaled corticosteroids (OR = 1.5; 95% CI = 0.9 to 2.6). CONCLUSIONS: Maternal use of corticosteroid medications was weakly associated with risk of hypospadias, but the association was negligible after adjustment for potential confounders.
OBJECTIVE: To explore whether women who reported corticosteroid use during pregnancy were more likely to deliver an infant with hypospadias than women who did not. STUDY DESIGN: The analysis encompassed data on deliveries with an estimated due date between 1997 and 2004 from the National Birth Defects Prevention Study, a large population-based, case-control study conducted in the United States. Included were 1165 cases of moderate to severe hypospadias and 3000 nonmalformed male controls. RESULTS: The mothers of 39 cases (3.3%) and 62 controls (2.1%) reported using a corticosteroid medication during the period extending from 4 weeks before conception to 14 weeks after conception. The odds ratio (OR) for any corticosteroid exposure versus no corticosteroid exposure was 1.6 (95% confidence interval [CI] = 1.1 to 2.5); after adjustment for maternal race/ethnicity, education, age, and study site, it was 1.3 (95% CI = 0.8 to 2.0). Analyses by route of administration and specific component suggest that elevated ORs occurred only for nasal spray/inhaled corticosteroids (OR = 1.5; 95% CI = 0.9 to 2.6). CONCLUSIONS: Maternal use of corticosteroid medications was weakly associated with risk of hypospadias, but the association was negligible after adjustment for potential confounders.
Authors: Rosa Sirianni; Bobbie A Mayhew; Bruce R Carr; C Richard Parker; William E Rainey Journal: J Clin Endocrinol Metab Date: 2005-07-12 Impact factor: 5.958
Authors: Suzan L Carmichael; Gary M Shaw; Verne Nelson; Steve Selvin; Claudine P Torfs; Cynthia J Curry Journal: Epidemiology Date: 2003-11 Impact factor: 4.822
Authors: Marlene Anderka; Allen A Mitchell; Carol Louik; Martha M Werler; Sonia Hernández-Diaz; Sonja A Rasmussen Journal: Birth Defects Res A Clin Mol Teratol Date: 2011-11-19
Authors: Jennifer N Lind; Sarah C Tinker; Cheryl S Broussard; Jennita Reefhuis; Suzan L Carmichael; Margaret A Honein; Richard S Olney; Samantha E Parker; Martha M Werler Journal: Pharmacoepidemiol Drug Saf Date: 2013-04-26 Impact factor: 2.890
Authors: E Garne; A Vinkel Hansen; J Morris; S Jordan; K Klungsøyr; A Engeland; D Tucker; D S Thayer; G I Davies; A-M Nybo Andersen; H Dolk Journal: BJOG Date: 2016-05-12 Impact factor: 6.531